Author, as appears in the article.: Escribano, Joaquin; Ferre, Natalia; Gispert-Llaurado, Mariona; Luque, Veronica; Rubio-Torrents, Carmen; Zaragoza-Jordana, Marta; Polanco, Isabel; Codoner, Francisco M; Chenoll, Empar; Morera, Mireia; Antonio Moreno-Munoz, Jose; Rivero, Montserrat; Closa-Monasterolo, Ricardo
Department: Medicina i Cirurgia
URV's Author/s: Closa Monasterolo, Ricardo / Escribano Subías, Joaquín / Ferré Huguet, Núria / Ferre Pallas, Natalia / Gispert Llauradó, Mariona / Luque Moreno, Verònica / RUBIO TORRENTS, MARÍA DEL CARMEN / Zaragoza Jordana, Marta
Keywords: Probiotics Patient safety Milk, human Microbiota Male Infant, newborn Infant formula Infant Immune system Humans Good health and well-being Flatulence Female Feces Double-blind method Diarrhea Constipation Bifidobacterium longum Anthropometry
Abstract: © 2018 International Pediatric Research Foundation, Inc. BackgroundIntestinal microbiota of breast-fed infants is plenty of beneficial bifidobacteria. We aimed to determine whether an infant formula supplemented with probiotic Bifidobacterium longum subsp. infantis CECT7210 (B. infantis IM1) is effective at reducing diarrhea incidence in healthy term infants.MethodsDouble blinded, randomized, multicenter, controlled clinical trial, where formula-fed infants (<3 months) received an infant formula supplemented (Probiotic) or not (Control) with 10 7 cfu/g of B. infantis IM1 over 12 weeks. Diarrheas, growth, digestive symptoms, stool bifidobacteria, and microbiota were assessed.ResultsIn all, 97 (Control) and 93 (Probiotic) infants were randomized, and 78 (Control) and 73 (Probiotic) completed the 12 week-follow-up. In the overall study period, a median of 0.29±1.07 and 0.05±0.28 diarrhea events/infant was observed in the Control and Probiotic groups, respectively (P=0.059). This trend to less diarrhea episodes in the Probiotic group reached statistical significance at 8 weeks (0.12±0.47 vs. 0.0±0.0 events/infant, P=0.047). Constipation incidence was higher (odds ratio (OR) 2.67 (1.09-6.50)) and stool frequency lower (2.0±1.0 vs. 2.6±1.3 stools/day, P=0.038) in the Control group after 4 weeks. No differences were found at other time points nor in other digestive symptoms, growth, or formula intake.ConclusionA B. infantis IM1-supplemented infant formula may reduce diarrhea episodes, being safe, well tolerated, and associated with lower constipation prevalence.
Thematic Areas: Serviço social Saúde coletiva Química Pediatrics, perinatology and child health Pediatrics Medicina ii Medicina i Interdisciplinar Ensino Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00313998
Author's mail: veronica.luque@urv.cat mariona.gispert@iispv.cat mariona.gispert@iispv.cat marta.zaragoza@urv.cat marta.zaragoza@urv.cat nuria.ferre@urv.cat ricardo.closa@urv.cat natalia.ferre@urv.cat joaquin.escribano@urv.cat
Author identifier: 0000-0003-2615-8175 0000-0002-4586-8079 0000-0002-4586-8079 0000-0002-9963-4163 0000-0002-2838-1525 0000-0002-5041-459X
Record's date: 2025-01-28
Paper version: info:eu-repo/semantics/acceptedVersion
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Paper original source: Pediatric Research. 83 (6): 1120-1128
APA: Escribano, Joaquin; Ferre, Natalia; Gispert-Llaurado, Mariona; Luque, Veronica; Rubio-Torrents, Carmen; Zaragoza-Jordana, Marta; Polanco, Isabel; Codo (2018). Bifidobacterium longum subsp infantis CECT7210-supplemented formula reduces diarrhea in healthy infants: A randomized controlled trial. Pediatric Research, 83(6), 1120-1128. DOI: 10.1038/pr.2018.34
Entity: Universitat Rovira i Virgili
Journal publication year: 2018
Publication Type: Journal Publications
Repositori URV